GE HealthCare to Lead €50.5 Million European Cardio-Oncology Consortium
GE HealthCare will lead COMPASS, a €50.5 million, five-year EU-funded consortium with over 60 partners to develop an AI-powered, end-to-end cardio-oncology care pathway. The initiative targets early cardiotoxicity detection, novel biomarker identification and integration of real-world, imaging and wearable data for personalised cancer patient management.
1. Consortium Launch and Funding
GE HealthCare launched COMPASS on 26 March, establishing a five-year, €50.5 million EU-funded consortium with over 60 partners under the Horizon Europe framework. The public-private initiative aims to create a comprehensive, patient-centred clinical pathway for cancer patients to reduce cardiovascular complications during treatment.
2. Objectives and AI Integration
COMPASS will focus on predicting cardiotoxicity risk and detecting cardiovascular disease at earlier stages by identifying novel biomarkers. The consortium will integrate real-world data, imaging, non-imaging, biomarkers and wearable information into AI-enabled predictive models and decision-support tools for personalised clinical care.
3. GE HealthCare's Role and Impact
As the lead industrial partner, GE HealthCare will coordinate development of an AI-powered, end-to-end care pathway connecting oncologists and cardiologists in clinical practice. This role could bolster its imaging and analytics solutions portfolio and strengthen its position in precision healthcare.
4. Academic and Industry Collaboration
King’s College London will serve as academic lead, providing scientific coordination and leveraging expertise in cardiology, oncology, molecular science, big data and AI. More than 60 industry, academic and clinical organizations will collaborate to support long-term heart health for cancer survivors.